More than 60 years after the first successful kidney transplant, for the monitoring of donor kidney acceptance is still relied on highly invasive biopsies. The histological control of biopsies is not only an invasive method, but also a very subjective one.
Because the need for a robust, non-invasive way of succession is very high, VITO went in search for suitable biomarkers that can indicate whether the transplant is a success. Within the partnership BioMargin European scientists search for useful biomarkers. These are body substances (blood, urine, kidney tissue,..) that contain information about the health of the new kidney.
In time, we hope to develop a tool that they can conclude much faster whether the donor kidney is accepted by the body and that no loss of function occurs.
In collaboration with the University of Antwerp, VITO specializes in proteomics, or the analysis of proteins and peptides (part of) an organism. VITO researchers in the BioMargin programme analyse urine samples from transplant patients with or without abnormal kidney biopsies and check out which proteins or peptides qualify as a biomarker to predict rejection.
- Consortium of 13 European partners from four countries
- Duration: 1 March 2013 – 1 March 2017
- Budget: € 6,000,000 grant from the European Commission